Cécile Palaric1,2,3, Serge Pilard4, Jean-Xavier Fontaine2, Julien Boccard5, David Mathiron1, Sébastien Rigaud1, Dominique Cailleu1, François Mesnard2, Yoann Gut3, Tristan Renaud3, Alain Petit3, Jean-Yves Beaumal3, Roland Molinié2. 1. Plateforme-analytique, Institut de Chimie de Picardie FR CNRS 3085, Université de Picardie Jules Verne, 33 rue Saint Leu, 80039, Amiens, France. 2. BIOPI EA 3900, Biologie des Plantes et Innovation, Université de Picardie Jules Verne, 1 rue des Louvels, 80000, Amiens, France. 3. Technologie Servier, 27 rue Eugène Vignat, 45000, Orléans, France. 4. Plateforme-analytique, Institut de Chimie de Picardie FR CNRS 3085, Université de Picardie Jules Verne, 33 rue Saint Leu, 80039, Amiens, France. serge.pilard@u-picardie.fr. 5. School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, 1211, Geneva 4, Switzerland.
Abstract
INTRODUCTION: Biotransformation constitutes an important aspect of the drug discovery process, to mimic human metabolism of active principal ingredient but also to generate new chemical entities. Several microorganisms such as fungi are well adapted to transform drug, whether at the stage of screening or for large-scale production. OBJECTIVES: Due to the high chemical complexity of the biotransformation media, it seems attractive to develop new analytical strategies in order to guarantee an adequate monitoring and optimize the production of targeted metabolites or drug candidates. METHODS: The model designed for this purpose concerns the biotransformation of a potential histamine H3 antagonist (S38093) in order to produce phase I metabolites. MS, NMR and chemometrics tools were used to monitor biotransformation reactions. RESULTS: First, a screening of eleven filamentous fungi was carried out by UHPLC-UV-MS and principal component analysis to select the best candidates. Subsequently, MS (tR, m/z) and NMR (1H, JRES) fingerprints associated with Consensus OPLS-DA multiblock approach were used to better understand the bioreaction mechanisms in terms of nutrient consumption and hydroxylated metabolites production. Then an experimental design was set up to optimize the production conditions (pH, kinetic) of these target metabolites. CONCLUSION: This study demonstrates how NMR and MS acquisitions combined with chemometric methods offer an innovative analytical strategy to have a grasp of functionalization mechanisms, and identify metabolites and other compounds (amino acids, nutrients, etc.) in complex biotransformation mixtures.
INTRODUCTION: Biotransformation constitutes an important aspect of the drug discovery process, to mimic human metabolism of active principal ingredient but also to generate new chemical entities. Several microorganisms such as fungi are well adapted to transform drug, whether at the stage of screening or for large-scale production. OBJECTIVES: Due to the high chemical complexity of the biotransformation media, it seems attractive to develop new analytical strategies in order to guarantee an adequate monitoring and optimize the production of targeted metabolites or drug candidates. METHODS: The model designed for this purpose concerns the biotransformation of a potential histamine H3 antagonist (S38093) in order to produce phase I metabolites. MS, NMR and chemometrics tools were used to monitor biotransformation reactions. RESULTS: First, a screening of eleven filamentous fungi was carried out by UHPLC-UV-MS and principal component analysis to select the best candidates. Subsequently, MS (tR, m/z) and NMR (1H, JRES) fingerprints associated with Consensus OPLS-DA multiblock approach were used to better understand the bioreaction mechanisms in terms of nutrient consumption and hydroxylated metabolites production. Then an experimental design was set up to optimize the production conditions (pH, kinetic) of these target metabolites. CONCLUSION: This study demonstrates how NMR and MS acquisitions combined with chemometric methods offer an innovative analytical strategy to have a grasp of functionalization mechanisms, and identify metabolites and other compounds (amino acids, nutrients, etc.) in complex biotransformation mixtures.
Authors: Mark J Gemkow; Adam J Davenport; Silke Harich; Bart A Ellenbroek; Andrea Cesura; David Hallett Journal: Drug Discov Today Date: 2009-03-06 Impact factor: 7.851
Authors: Marlon Cowart; Robert Altenbach; Lawrence Black; Ramin Faghih; Chen Zhao; Arthur A Hancock Journal: Mini Rev Med Chem Date: 2004-11 Impact factor: 3.862
Authors: Mohamed-Elamir F Hegazy; Tarik A Mohamed; Abdelsamed I ElShamy; Abou-El-Hamd H Mohamed; Usama A Mahalel; Eman H Reda; Alaa M Shaheen; Wafaa A Tawfik; Abdelaaty A Shahat; Khalid A Shams; Nahla S Abdel-Azim; Fayza M Hammouda Journal: J Adv Res Date: 2014-11-22 Impact factor: 10.479
Authors: Thomas De Vijlder; Dirk Valkenborg; Filip Lemière; Edwin P Romijn; Kris Laukens; Filip Cuyckens Journal: Mass Spectrom Rev Date: 2017-11-09 Impact factor: 10.946